Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$376.37 USD

376.37
1,192,082

+1.43 (0.38%)

Updated Aug 7, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

Zacks Equity Research

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

by Zacks Equity Research

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

Zacks Equity Research

SenesTech (SNES) Expands in the Netherlands With Q-chem Deal

by Zacks Equity Research

SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.

Zacks Equity Research

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

Zacks Equity Research

Thermo Fisher (TMO) Introduces Dionex Inuvion IC system

by Zacks Equity Research

Thermo Fisher's (TMO) Dionex Inuvion system helps labs operate more effectively by providing simple, adjustable workflows and a small footprint.

Zacks Equity Research

QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

by Zacks Equity Research

QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.

Zacks Equity Research

National Vision (EYE) Hurt by Business Closure, Macro Woe

by Zacks Equity Research

National Vision's (EYE) impending termination of the long-term partnership with Walmart is likely to significantly impact its business.

Zacks Equity Research

IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution

by Zacks Equity Research

IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.

Zacks Equity Research

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

by Zacks Equity Research

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

Zacks Equity Research

Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall

by Zacks Equity Research

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.

Zacks Equity Research

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance

Zacks Equity Research

Edwards (EW) Gains From Balanced Core Growth and New Launches

by Zacks Equity Research

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Zacks Equity Research

Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi

by Zacks Equity Research

Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.

Zacks Equity Research

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

by Zacks Equity Research

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Zacks Equity Research

Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.

Zacks Equity Research

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

by Zacks Equity Research

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

Zacks Equity Research

CVS Health (CVS) Gains From Digital Adoption Amid Competition

by Zacks Equity Research

CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Zacks Equity Research

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

by Zacks Equity Research

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Zacks Equity Research

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

Zacks Equity Research

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

by Zacks Equity Research

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.